Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Large Volume Increase – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw an uptick in trading volume on Thursday. 328,839 shares traded hands during trading, an increase of 34% from the previous session’s volume of 246,080 shares. The stock last traded at $19.0580 and had previously closed at $19.31.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, Nomura raised Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Down 1.5%

The company has a market cap of $62.64 billion, a PE ratio of 20.68 and a beta of 0.60. The firm’s 50-day simple moving average is $21.18 and its two-hundred day simple moving average is $23.46.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. As a group, analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.